Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) — Cash Flow-to-Debt Ratio
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) has a Cash Flow-to-Debt Ratio of -0.12x as of March 2026, meaning its operating cash flow of $-349.69K could theoretically repay 0% of its total liabilities ($3.04 Million) in one year. See LABT equity financing ratio to measure how much of total assets are equity-financed.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Lakewood-Amedex Biotherapeutics Inc. Common Stock Cash Flow-to-Debt Ratio (2023–2025)
Historical debt coverage capacity for Lakewood-Amedex Biotherapeutics Inc. Common Stock across 3 annual periods. See Lakewood-Amedex Biotherapeutics Inc. Com leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Annual Cash Flow-to-Debt Ratio for Lakewood-Amedex Biotherapeutics Inc. Common Stock (2023–2025)
Year-by-year debt coverage analysis for Lakewood-Amedex Biotherapeutics Inc. Common Stock. For the full cash flow conversion analysis, see Lakewood-Amedex Biotherapeutics Inc. Com (LABT) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.80x | $-1.94 Million | $2.45 Million | ▲ +90.8% |
| 2024 | -8.66x | $-5.72 Million | $660.97K | ▼ -196.7% |
| 2023 | -2.92x | $-6.82 Million | $2.34 Million | — |